Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
zidovudine, lamivudine and nevirapine · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| (A) zidovudine, lamivudine and nevirapine | DRUG | - |
| (B) zidovudine, lamivudine and efavirenz | DRUG | - |
| (C) zidovudine, didanosine, and nevirapine | DRUG | - |
| (D) zidovudine, didanosine, and efavirenz | DRUG | - |
| (E) stavudine, lamivudine, and nevirapine | DRUG | - |
| (F) stavudine, lamivudine and efavirenz | DRUG | - |
| Adherence Strategy Standard of Care (SOC) | PROCEDURE | - |
| Adherence Strategy Community-Based DOT | PROCEDURE | - |
Inclusion Criteria:(1) HIV infection indicated by (a) positive ELISA in two separate blood samples, the second no more than eight weeks prior to randomization), (b) CD4 cell count of less than 200 cells/ml OR CD4 cell count between 201-350 with plasma HIV-1 RNA level of greater than 55,000 copies/ml...
Zidovudine, lamivudine and nevirapine is a combination of three antiretroviral drugs used for the treatment of AIDS and HIV infection. It is being developed by Bristol-Myers Squibb Company (BMY) as a small molecule therapy for infectious disease.
Zidovudine, lamivudine and nevirapine targets HIV reverse transcriptase. Zidovudine and lamivudine are nucleoside reverse transcriptase inhibitors, while nevirapine is a non-nucleoside reverse transcriptase inhibitor. Together they block viral replication by inhibiting this enzyme.
Bristol-Myers Squibb Company (ticker: BMY) is developing zidovudine, lamivudine and nevirapine. The drug is a combination of three small molecule antiretroviral agents intended for the treatment of AIDS and HIV infection.
Zidovudine, lamivudine and nevirapine is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 trial has been completed, with no active trials currently ongoing.
Zidovudine, lamivudine and nevirapine was studied in a Phase 3 trial with NCT number NCT00197613, titled "The Adult Antiretroviral Treatment and Resistance Study (Tshepo)". This completed trial enrolled 650 participants with AIDS or HIV infection in Botswana, with a minimum age of 18 years.